Bengaluru-based Pandorum Technologies has raised $18 million to scale its regenerative therapies, focusing on 3D bio-printed human tissues and organoids for treating corneal blindness, liver failure, and lung disorders. The funding will fuel clinical trials, global manufacturing, and expansion into key markets, advancing its mission to solve the organ shortage crisis through tissue engineering.
Glimpse:
Pandorum’s $18 million round supports acceleration of its flagship programs: bio-engineered corneas for vision restoration, liver tissue patches for acute liver failure, and lung therapeutics. The company’s proprietary 3D bioprinting platform creates functional human tissues that mimic native biology. The capital will drive regulatory progress, scale GMP production, and pursue international partnerships to bring regenerative solutions closer to patients worldwide.
Pandorum Technologies, a pioneer in 3D bioprinted regenerative therapeutics, has closed an $18 million funding round to propel its pipeline toward clinical and commercial milestones. The investment, announced in early 2026, will primarily support late-stage development of its lead candidates: bio-fabricated corneas to treat corneal blindness, liver tissue constructs for bridging acute liver failure, and early-stage lung regeneration programs.
Founded on breakthrough work in tissue engineering, Pandorum uses its patented platform to 3D-print living human tissues with precise control over cell types, extracellular matrix, and vascularization. Its corneal tissue product has shown promising preclinical and early human data for restoring sight in patients with severe corneal damage an area with massive unmet need due to donor shortages.
The fresh funds will be directed toward: Advancing clinical trials in India and key global markets Scaling GMP-compliant manufacturing for consistent, high-quality tissue production Strengthening regulatory pathways with agencies such as CDSCO, US FDA, and EMA Forging strategic partnerships for distribution and co-development
Pandorum’s work addresses one of healthcare’s biggest challenges: the global shortage of donor organs. By creating transplantable or regenerative tissues in the lab, the company aims to reduce dependency on donors and offer life-changing therapies for end-stage organ failure.
The round reflects growing investor confidence in India’s biotech innovation and the rising global demand for regenerative medicine solutions.
“With this funding, we’re moving fast from lab to patients turning regenerative medicine into real-world cures for blindness, liver failure, and beyond.”
By
HB Team
